Eli Lilly Debt to Equity Ratio 2006-2018 | LLY

Current and historical debt to equity ratio values for Eli Lilly (LLY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Eli Lilly debt/equity for the three months ending June 30, 2018 was 0.79.
Eli Lilly Annual Debt/Equity Ratio
2017 1.17
2016 0.73
2015 0.55
2014 0.52
2013 0.30
2012 0.37
2011 0.52
2010 0.56
2009 0.70
2008 1.55
2007 0.37
2006 0.34
2005 0.60
Eli Lilly Quarterly Debt/Equity Ratio
Q2 2018 1.05
Q1 2018 0.80
Q4 2017 1.17
Q3 2017 0.90
Q2 2017 0.87
Q1 2017 0.73
Q4 2016 0.73
Q3 2016 0.60
Q2 2016 0.64
Q1 2016 0.54
Q4 2015 0.55
Q3 2015 0.53
Q2 2015 0.54
Q1 2015 0.55
Q4 2014 0.52
Q3 2014 0.32
Q2 2014 0.30
Q1 2014 0.29
Q4 2013 0.30
Q3 2013 0.31
Q2 2013 0.35
Q1 2013 0.37
Q4 2012 0.37
Q3 2012 0.34
Q2 2012 0.39
Q1 2012 0.37
Q4 2011 0.52
Q3 2011 0.47
Q2 2011 0.47
Q1 2011 0.48
Q4 2010 0.56
Q3 2010 0.58
Q2 2010 0.67
Q1 2010 0.64
Q4 2009 0.70
Q3 2009 0.75
Q2 2009 0.90
Q1 2009 1.10
Q4 2008 1.55
Q3 2008 0.34
Q2 2008 0.31
Q1 2008 0.32
Q4 2007 0.37
Q3 2007 0.38
Q2 2007 0.44
Q1 2007 0.47
Q4 2006 0.34
Q3 2006 0.37
Q2 2006 0.53
Q1 2006 0.54
Q4 2005 0.60
Q3 2005 0.57
Q2 2005 0.46
Q1 2005 0.40
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $113.918B $22.871B
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $380.918B 18.20
Pfizer (PFE) United States $260.438B 15.24
Novartis AG (NVS) Switzerland $199.232B 17.09
Merck (MRK) United States $190.836B 16.85
AbbVie (ABBV) United States $140.343B 13.71
Novo Nordisk (NVO) Denmark $116.068B 18.56
Sanofi (SNY) France $110.732B 14.02
Bristol-Myers Squibb (BMY) United States $100.933B 18.27
GlaxoSmithKline (GSK) United Kingdom $98.875B 13.20
AstraZeneca (AZN) United Kingdom $95.541B 10.51